Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
about
KASL clinical practice guidelines: management of hepatitis CProfile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infectionAlcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infectionsReal-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone.Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations.SASLT guidelines: Update in treatment of Hepatitis C virus infection.Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus LamivudineDirect-acting antiviral agents for HCV infection affecting people who inject drugs.Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.Management of HCV infection in the penitentiary setting in the direct-acting antivirals era: practical recommendations from an expert panel.Clinical Pharmacokinetics of Paritaprevir.Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis.Ultra-performance liquid chromatography tandem mass spectrometry for determination of Direct Acting Antiviral drugs in human liver fine needle aspirates.Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C.Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016.Retention in buprenorphine treatment is associated with improved HCV care outcomes.Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection.Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all.Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.Recommendations for the management of hepatitis C virus infection among people who inject drugs.Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data?Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies.Darunavir-based Antiretroviral Therapy may Affect the Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in HCV/HIV-1 Coinfected Patients.Hepatitis C virus prevention and care for drug injectors: the French approachOmbitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 42017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis CEfficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials
P2860
Q26752471-06D2DE68-218A-4F84-A489-29ABBCCB06E7Q26775825-7F322055-3298-4907-96B0-5B0546335CDEQ28070280-EF7FDFEB-FB76-44AE-8421-9970A28AF10AQ33557819-A349CDDC-A5CC-4A74-AD7D-3929383BAF40Q33853664-19358837-E515-4841-BAD5-6800AFB0F499Q35960681-65983B3B-B44B-4A59-B347-F147BE70D550Q36335281-21215D51-E62A-45E7-95C3-094B9C31D6E8Q36519126-21795B28-E509-457D-A67E-19F2E7EF1B2EQ37216507-624DFE98-CC63-48F4-B462-DA51F93FE6D4Q37287684-C04951B0-B175-4BAB-91EE-B66B605DB3D2Q38613271-2790AC49-8DA6-4108-A01F-99E0AA2A9304Q38661825-CD59B4BD-FC08-495D-9180-70FF57568825Q38692113-9EED6699-6BF0-49AF-90AF-7023BA6299D8Q38927209-0F6B0A8B-AAAC-4A66-99A3-6914F3DB7A00Q38929010-BEA5FC89-D141-4892-96B4-6DB89ADBAB5DQ39057197-07239258-D9C1-4047-9FBD-A52A2FC23BDCQ39150134-D8E88E9A-E1DD-4886-9B18-3D55E6B0D2C9Q39357557-3A7F2A02-C350-4FDF-941F-9CA85A3BAE37Q39778146-BC601709-9998-453A-896D-5AB413A914C8Q40058097-F0532C3F-0C83-494C-83E1-6C42480DDBC9Q40263873-81BE5F05-613E-4812-94B6-905B0D622115Q40285894-6CF8BF7A-F5A2-4D45-A4F9-1E9899D3A2E9Q40292229-7E79E5F8-2FEC-4313-B3E5-F0C6D020E55CQ40317993-F90DF6AE-ECC0-4686-B98D-947914DF5F76Q40341184-56BA5CFE-C8D0-480E-A7A4-53DDD827B470Q40565822-54E15580-C87A-46DF-AEA2-E55846795720Q40565832-6CC9C4FF-DC73-4103-B054-63BBBEAFE728Q40641871-777C354A-C985-42F0-A9C1-2974D526869FQ40684442-E9C23FC6-3871-4A9D-B5A9-9EFBCA8F37ECQ41047662-08D6A396-5A6E-4236-9BF0-42109242CC7DQ43895313-E3F532BB-E9D1-4CEE-91A7-CA78E263F8F2Q49953662-524E2ACB-2297-4230-9136-F9A9B8FE6600Q50863769-FF62585B-72EE-4372-8631-0BBE15CA0BEBQ57144432-C1C7186A-5376-41E0-8788-B8800A880274Q58582162-2DD885F5-78EB-4E01-9DFD-21B27127B918Q58788714-B2FBF26B-5D53-46E0-9F81-751170597F08Q59133541-DED10A9B-3A39-4C85-9C04-AFBBFC542B63
P2860
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Ombitasvir/paritaprevir/r and ...... on methadone or buprenorphine.
@en
type
label
Ombitasvir/paritaprevir/r and ...... on methadone or buprenorphine.
@en
prefLabel
Ombitasvir/paritaprevir/r and ...... on methadone or buprenorphine.
@en
P2093
P1476
Ombitasvir/paritaprevir/r and ...... on methadone or buprenorphine.
@en
P2093
Akshanth R Polepally
Barbara McGovern
Daniel E Cohen
Edward Galen
Franco Felizarta
Humberto Aguilar
J Greg Sullivan
Jacob Lalezari
Kris V Kowdley
Martin King
P304
P356
10.1016/J.JHEP.2015.03.029
P577
2015-04-01T00:00:00Z